LATEST HEALTH NEWS
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children aged 6-11 years.
from Medindia Health News https://ift.tt/3vkuRLn
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children aged 6-11 years.
from Medindia Health News https://ift.tt/3vkuRLn
No comments
Thanks for comment via will connect you within 24 hours.